Otsuka Pharmaceutical Co., Ltd.

April 5, 2024

Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry in the U.S.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that its U.S. subsidiaries, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) launched My Mental Health Journey, a longitudinal registry study that aims to advance research in depression and mental health. Verily Life Sciences LLC (Verily), a precision health technology company, will recruit participants and run the study.

The My Mental Health Journey registry will enroll U.S.-based adults experiencing symptoms of depression to help Otsuka better understand mental health conditions, such as major depressive disorder, across time and in the real-world setting. Adults over the age of 18 will participate in this observational study by securely sharing their unique depression journeys through periodic, self-guided assessments and digital data collection. In addition to contributing to mental health and depression research, participants will gain access to the latest information on depression and other mental health related topics, and have a more streamlined path to participate in future clinical research studies.

Insights generated from the registry will be used by Otsuka to power future research, informing areas such as trial design, site selection, and health outcomes research.

Otsuka has worked with Verily since 2019 to apply novel clinical trial solutions across its product portfolio. As Otsuka and Verily expand the registry, they plan to integrate additional data sources with participant consent, launch additional cohorts and sub-studies, and develop novel digital biomarkers to further research.

About Verily

Verily Life Sciences LLC is an Alphabet health technology company focused on research, care, and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable. For more information, please visit: